NeoGenomics, Inc. Payments to Fund Long-term Loans to Related Parties
NeoGenomics, Inc. (NEO) reported Payments to Fund Long-term Loans to Related Parties of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-20.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaymentsToFundLongtermLoansToRelatedParties · last filed 2024-02-20
- NeoGenomics, Inc. payments to fund long-term loans to related parties for the quarter ending 2022-12-31 was $0.00.
- NeoGenomics, Inc. payments to fund long-term loans to related parties for the quarter ending 2022-09-30 was $0.00.
- NeoGenomics, Inc. payments to fund long-term loans to related parties for the quarter ending 2022-06-30 was $0.00.
- NeoGenomics, Inc. payments to fund long-term loans to related parties for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- NeoGenomics, Inc. payments to fund long-term loans to related parties for fiscal 2023 was $0.00.
- NeoGenomics, Inc. payments to fund long-term loans to related parties for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- NeoGenomics, Inc. payments to fund long-term loans to related parties for fiscal 2021 was $15.00M.
- NeoGenomics, Inc. payments to fund long-term loans to related parties for fiscal 2020 was $0.00.
| Period end | Payments to Fund Long-term Loans to Related Parties 3 month | Payments to Fund Long-term Loans to Related Parties 6 month | Payments to Fund Long-term Loans to Related Parties 9 month | Payments to Fund Long-term Loans to Related Parties 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-20 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $0.00 derived: sum of 2 quarters · filed 2024-02-20 | $0.00 derived: sum of 3 quarters · filed 2024-02-20 | $0.00 10-K · filed 2024-02-20 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2024-02-20 | $0.00 derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-20 | $0.00 derived: sum of 3 quarters · filed 2024-02-20 | $0.00 derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $0.00 derived: sum of 2 quarters · filed 2024-02-20 | $0.00 derived: sum of 3 quarters · filed 2024-02-20 | $15.00M 10-K · filed 2024-02-20 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $15.00M 10-Q · filed 2022-11-08 | $15.00M derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $15.00M 10-Q · filed 2022-08-09 | $15.00M derived: sum of 3 quarters · filed 2023-02-24 | $15.00M derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-03-31 | $15.00M 10-Q · filed 2022-05-09 | $15.00M derived: sum of 2 quarters · filed 2023-02-24 | $15.00M derived: sum of 3 quarters · filed 2023-02-24 | $15.00M derived: sum of 4 quarters · filed 2023-02-24 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $0.00 derived: sum of 2 quarters · filed 2023-02-24 | $0.00 derived: sum of 3 quarters · filed 2023-02-24 | $0.00 10-K · filed 2023-02-24 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |